Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : Kevin Young CBE, Gilead's Chief Operating Officer, to Retire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:02pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Gilead Sciences, Inc. (Nasdaq: GILD) announced that Kevin Young CBE, Chief Operating Officer, plans to retire, effective early 2018. Mr. Young will remain with Gilead through the first quarter of next year and in an advisory capacity thereafter (see also Pharmaceutical Companies).

Mr. Young joined Gilead in 2004 to lead the company's worldwide commercial operations. He oversaw the introduction of multiple new products, including the first single tablet regimens for HIV and the first oral direct acting antiviral regimens for chronic hepatitis C. In 2014, Mr. Young retired from his full-time role and served as a senior advisor to Gilead until 2016, when he returned to assume the role of Chief Operating Officer. Prior to Gilead, he spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise Physiology from Liverpool and Nottingham, England. In 2011, he was appointed a Commander of The British Empire, one of Great Britain's highest civilian honors, in recognition of his "services to the healthcare and pharmaceutical industries."

"Since Kevin joined Gilead in 2004, he has worked tirelessly to build Gilead's commercial success across numerous therapeutic areas and geographies," said John Martin, PhD, Executive Chairman. "Together with the Board of Directors, I am grateful that he came out of semi-retirement in May 2016 to strengthen Gilead and help establish the strategy and execute on plans for our next phase of growth in cell therapy."

"Kevin has had an impact on Gilead - and by extension on the field of medicine and the lives of patients - that is seldom seen," said John Milligan, PhD, President and Chief Executive Officer. "Those who have had the opportunity to work alongside Kevin know that he possesses both a deep commitment to his work and unparalleled leadership abilities. I am delighted that he will be helping us manage through a period of change over the next several months and I am deeply grateful to Kevin for his contributions to Gilead and to the lives of millions of people around the world." About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Keywords for this news article include: Pharmaceutical Companies, Biopharmaceuticals, Drugs and Therapies, Gilead Sciences Inc..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
10/16 GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
10/16 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday Oc..
10/12 GILEAD SCIENCES : An Application for the Trademark "NASH360" Has Been Filed by G..
10/12 GILEAD SCIENCES : High-Stakes Gilead Case Lands Fish & Richardson Principals Jua..
10/12 GILEAD SCIENCES : Completes Acquisition of Kite Pharma, Inc.
10/12 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday, O..
10/12 GILEAD SCIENCES : Presents Results From Phase 3 Study Evaluating Patients Who Sw..
10/12 GILEAD SCIENCES : Patent Issued for Co-Crystals, Salts and Solid Forms of Tenofo..
10/12 GILEAD SCIENCES : Announces New License Agreement With the Medicines Patent Pool..
10/12 Loncar Cancer Immunotherapy Index Announces Merger Replacements
More news
News from SeekingAlpha
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 GILEAD : My Only 'Buy 'Til You Die' Investment,  A Deep Due Diligence Dive
10/16 Q3 ROUNDUP : Top 5 Performing Knives
10/15 DIVIDEND INCOME UPDATE : September 2017
10/12 MONTHLY REVIEW OF DIVGRO : September 2017
Financials ($)
Sales 2017 25 905 M
EBIT 2017 16 060 M
Net income 2017 10 607 M
Debt 2017 12 394 M
Yield 2017 2,61%
P/E ratio 2017 10,13
P/E ratio 2018 11,92
EV / Sales 2017 4,57x
EV / Sales 2018 5,04x
Capitalization 106 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 84,4 $
Spread / Average Target 3,9%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.65%106 002
REGENERON PHARMACEUTICALS20.67%47 464
VERTEX PHARMACEUTICALS107.56%38 551
ACTELION23.24%29 919
GENMAB22.08%13 910
EXELIXIS, INC.66.06%7 277